Table 3.

Potential prespecified sources of heterogeneity explored among studies reporting SUA levels of patients with psoriasis vs. controls.

Prespecified source of heterogeneity	No. of studies	Random-effects meta-regression (95% CI)	P-value
Source population			0.876
Inpatient	6	0.879 (0.062–12.367)
Outpatient	11	0.930 (0.295–2.932)
Not clear	8	0.913 (0.250–3.330)
Location			0.873
No	0	N/A
Yes	24	0.813 (0.680–9.727)
Not clear	2	0.667 (0.034–13.215)
Study design			0.397
Cohort	18	0.945 (0.083-10.711)
Cross-sectional	8	0.554 (0.045-6.779)
Study quality			0.372
High (≥7 stars)	8	0.625 (0.049-8.005)
Medium (4–6 stars)	18	0.894 (0.076-10.573)
Poor (<4 stars)	0	N/A
Severity of psoriasis			0.485
No distinction	16	0.926 (0.078–10.956)
Mild vs. severe	10	0.634 (0.051–7.826)
Psoriatic arthritis included			0.518
No	4	0.838 (0.052–13.568)
Yes	6	0.960 (0.0653–14.113)
Not clear	16	0.741 (0.057–9.648)
Outcome ascertainment			0.786
Billing data	10	0.612 (0.050–7.46)
Chart review	16	0.947 (0.081–11.05)
Examination	0	N/A
Analysis of outcome			0.249
Primary	18	1.008 (0.096–10.541)
Secondary	8	0.473 (0.420–5.334)

CI, confidence interval; N/A, not applicable.